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Abstract: Transfusion–acquired babesiosis can be an asymptomatic or self-limited febrile 
hemolytic illness in a healthy host. A persistent, relapsing and/or fulminant course with 
the development of life threatening complications may be seen in immunocompromised 
or splenectomized patients. As in malaria, erythrocyte parasitemia is often associated 
with non-immune hemolysis, and can be treated with erythrocytapheresis. Just as warm 
autoantibodies have been reported in malaria infection, the development of autoantibody-
mediated immune hemolysis has been reported in babesiosis. We treated a previously 
healthy male with multiple injuries from a motor vehicle accident necessitating massive 
transfusion.  His hospital course was complicated. Late in the hospitalization, his blood 
smear revealed Babesia microti, confirmed by PCR study and serology.  Specific 
antiobiotic therapy was begun, and severe hemolysis from a high parasite burden required 
red blood cell exchange which led to rapid abatement of the hemolysis. He had a positive 
DAT (IgG with a pan-reactive eluate) but no serum autoantibody.  This persisted for 10 
days following cessation of hemolysis, and became negative while still on antibiotics 
while his parasite burden became undetectable. Reports of autoimmunity caused by 
babesiosis often have severe hemolysis from their autoantibodies, but our case shows that 
immune hemolysis from autoantibodies in babesiosis is not a constant finding. The nature 
of the autoantigen is unknown. 
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Introduction 
 
Babesiosis is a zoonotic protozoan disease transmitted primarily by genus Ixodes ticks.  
Babesia microti and Babesia divergens are the two most common species of babesia 
infecting humans in the United States [1]. These parasites can infest erythrocytes and 
cause malaria-like illness. There has been an increased awareness of transfusion-acquired 
babesiosis (TAB) in the last two decades, with more than 50 cases reported since 1980 
[2]. Several factors contribute to the risk of TAB transmission. Most donor infections are 
asymptomatic, and currently there is no licensed donor screening assay for Babesia [3].  
Tick borne pathogens can survive in refrigerated [4, 5] or frozen-thawed [6] blood 
components.  
 
Infections with Babesia can run a varied clinical course. Healthy hosts may have an 
asymptomatic or self-limited febrile illness. Both adults and children who are immune 
compromised or have undergone splenectomy are at risk to develop severe symptomatic 
infections with malaise, myalgias, fever, chills and sweating. These patients may have a 
chronic persistent, relapsing or fulminant course [1] and develop life threatening 
complications, including acute respiratory distress syndrome [7], disseminated 
intravascular coagulation and acute renal failure [8]. Human babesiosis is often 
associated with non-immune hemolysis from the erythrocytic parasites, and occasionally 
thrombocytopenia in more severe cases.  
Many infections or inflammatory diseases may cause immune dysregulation; and 
bacterial, viral and parasitic pathogens have been known to stimulate autoantibodies that 
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crossreact with similar antigens on erythrocytes. Autoimmunity to red blood cells in 
babesiosis has been documented in humans [9, 10] just as it has been reported in malaria 
infection [11, 12, 13]. 
  
Case Report 
 
A 61 year old, Group O, Rh negative male, with a negative antibody screen was in a 
motor vehicle accident on August 5 in which he sustained multiple injuries including 
cervical burst fracture at  C7, multilevel thoracic spinal compression fractures, scapular 
fracture, multiple rib fractures and severe intraabdominal injuries. During transport to our 
facility he became hypotensive, and responded to pressors, fluid resuscitation and 
emergency blood transfusion. Exploratory laparotomy revealed mesenteric hematoma, 
hemoperitoneum, splenic laceration requiring splenectomy, and liver laceration.  The 
hemorrhage was controlled and while in the OR the patient underwent application of 
cranial traction to treat his unstable cervical fracture. He received a total of 19 units of 
packed red cells (12 Rh negative, 7 Rh positive), 2 Rh negative apheresis platelets, 18 
units of FFP and 10 units of cryoprecipitate while he had active bleeding during his first 
36 hours. Three days later (day +4), he returned to the OR for abdominal washout, 
removal of packs, wound closure and placement of feeding gastrostomy tube and 
required no transfusion. On day +6 he underwent anterior decompression and 
stabilization of the cervical fracture requiring no blood intraoperatively, but 2 units of Rh 
negative red cells were given in the post-op period. His hospital course and recovery 
were complicated by multiple episodes of aspiration pneumonia, urosepsis and central 
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line infection. He was treated with multiple antibiotics, including Zosyn, Ciprofloxacin, 
Vancomycin and Tobramycin during this time.  
Additional red blood cell transfusions were needed beginning on day +41 because of 
worsening anemia. Compatibility testing revealed he had developed alloantibodies to D 
and E but he did not have a positive DAT or evidence of a serum autoantibody.  His Rh 
typing was Group O, Rh negative with no mixed field appearance at that time.  On day 
+51, a weakly positive DAT for IgG was detected. An eluate (Elukit method) reacted 
with all D-E- cells tested. The serum again did not demonstrate an autoantibody or 
additional alloantibody. His LDH was 1052 U/L and reticulocyte count 9.3% (absolute 
291,000 B/L).  To evaluate whether he had a drug antibody, studies at a reference 
laboratory demonstrated no reactivity using the two antibiotics he was still receiving 
which have most commonly been implicated, Zosyn and Vancomycin. 
Between day +41 and day +51, his hemoglobin dropped from 9.6 to 7.2 gm/dL despite 
the transfusion of 3 units of Rh negative red blood cells and the reticulocyte count 
remained elevated (absolute 292,000 B/L). The serum haptoglobin was <6 gm/dL and a 
new serum alloantibody was detected, anti-C. The anti-C was not revealed in repeat 
elution studies, although the DAT was still positive for a pan-reactive antibody. 
On day +54, examination of his blood smear revealed numerous red cells with 
intracellular parasites suggestive of Babesia microti, subsequently confirmed by PCR and 
serology. Retrospectively, blood smears retrieved from the previous few days revealed 
scattered B. microti infected RBCs that had been overlooked.  The level of parasitemia on 
day +54 was 7.8%. Treatment with Gentimycin and Azithromycin was initiated, but 
hemolysis continued despite several days of antibiotic treatment. On hospital day +57, he 
 6 
had worsening symptomatic hemolytic anemia, with Hgb dropping to 5.6 gm/dL, 
increasing reticulocytosis and symptomatic tachycardia, hypoxia and dyspnea. Red blood 
cell exchange with 8 units of Rh negative red blood cells was performed with rapid 
clinical improvement following the exchange transfusion.  Evidence of hemolysis abated 
rapidly. The exchange dramatically reduced the parasite burden to 0.6% by the next day 
and to <0.003% on day +63.  A blood smear on day +67, ten days after the exchange, was 
clear of all parasites. The positive DAT for IgG persisted for 10 days following cessation 
of his hemolysis and then became nondetectable. The patient continued to improve 
clinically and was eventually discharged home after completing his course of antibiotics. 
No further transfusion was required after the red cell exchange and his Hgb remained 
stable. His elevated reticulocytes began declining after the exchange and returned to 
normal within nine days. 
 
Epidemiology 
 
The patient was a retired state trooper who lived in central Pennsylvania.  He denied a 
history of known tick bites and his only exposure to fields or wooded areas was a round 
of golf played a few weeks prior to his MVA. Given the usual 1-4 week incubation 
period for community acquired babesiosis, TAB was suspected given its later 
symptomatic onset.  With the cooperation of our blood center, the infection was traced to 
one of the donors of the units used during the massive transfusion on August 5. High titer 
Babesia microti IgM antibody (IFA of 1:512) was found in a 4-month post-donation 
sample. This donor lived in southern New Jersey, a known area of Babesia microti 
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infestation.  The PCR assay of the follow-up donor sample was negative and no residual 
material from the original donation could be recovered. The case was reported as TAB 
associated with the transfusion of red cells, most probably from the donor with high titer 
IgM antibodies.  
 
Discussion 
 
The incubation period for TAB may be longer than after a tick bite [1], although the 
delayed onset in our patient may also have been due to the antibiotics he had been on, 
some of which had partial effectiveness against B. microti.  The severity of TAB in our 
patient can be attributed to his asplenic state, as has been reported, and may have become 
more clinically apparent as his antibiotic therapies were completed.   
Our patient’s positive DAT and apparent autoantibody could have been caused by 
delayed transfusion reactions from anti-D, anti-E and anti-C induced by the Rh d 
incompatible emergency transfusions on day 0 and day +1.  However, the time course of 
the serologic findings are much more compatible with this being TAB-associated 
autoantibody.  Our patient’s course of hemolysis was clearly different from the other 
cases of TAB associated autoantibody reported in the literature.   
In a series of cases, Wolf et al, [9] reported that three of 30 patients with clinical and 
laboratory evidence of community acquired babesiosis, all asplenic, had positive DAT’s 
due to IgG but not complement. Eluates prepared from the patients’ red blood cells 
reacted with all cells but were markedly less reactive with Rh null cells. One of the 
patients developed marked hemolysis with 8% Babesia microti parasitemia following 
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travel to an endemic area. She was treated with red blood cell exchange and developed 
anti-E and anti-c. She received multiple transfusions of antigen negative blood, but 
continued to have hemolysis, despite low parasitemia (0.1%), and persistence of the 
autoantibody.  This patient’s continued immune hemolysis responded to treatment with 
steroids.  
The second report of babesiosis with autoantibodies was described by Evenson, et al, 
[10]. A 47 year old transplant recipient who had been receiving immunosuppressive 
therapy for 8 years probably acquired babesia from a tick bite during travel to an endemic 
area. The patient was treated with antibiotics and red blood cell exchange and stabilized. 
Hemolysis improved transiently, but a few weeks after being discharged from the 
hospital he was readmitted with worsening parasitemia. The DAT was positive for IgG, 
but not C3. Red blood cell exchange was performed for the second time and his immune 
suppression therapy was changed. Over the next six weeks he had increasing paresitemia 
and another two episodes of worsening hemolysis with a positive DAT for both IgG and 
C3. He was treated with antibiotics and red blood cell and plasma exchanges. Hemolysis 
appeared to be due primarily to autoantibody rather than parasite burden. When the 
antibody was no longer detectable parasitemia increased from <1% to 8.2% but he had no 
worsening of hemolysis. Continued treatment with Clindamycin, Atovaquone and 
Quinidine alone led to a drop in parasitemia. After two more months no parasites were 
detected in his red blood cells and the DAT was negative. This patient had persistent 
parasitemia, and his autoantibody contributed to hemolysis over four months, but 
disappeared before the eradication of infection. 
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Our experience underscores that TAB may cause severe hemolysis which can be 
dramatically improved by exchange erythrocytopheresis.  Our experience also 
underscores that TAB may cause the development of autoantibodies just as in community 
acquired babesiosis, but immune hemolysis is not a constant finding and the autoantibody 
may be transient and clinically innocuous.  
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